Skip to main content

Study

Lutein and Zeaxanthin May Reduce Macular Degeneration Risk in Older Adults

Taking lutein and zeaxanthin supplements may reduce the risk of advanced age-related macular degeneration in older adults.

Study Credibility: Medium5.6/10Some supporting evidenceStudy has limitationsUse with caution
PublishedMay 2026Last reviewedOct 2026
Email this

Summary

In plain language

Recent research suggests that adding lutein and zeaxanthin to daily supplements might help lower the risk of progressing to advanced age-related macular degeneration (AMD) in seniors. This study followed participants over ten years and found that those taking these supplements had a lower chance of developing severe AMD, compared to those who took beta-carotene, which was linked to a higher risk of lung cancer, especially in former smokers. The findings are important because AMD is a common cause of vision loss in older adults. Seniors should consider discussing with their healthcare providers whether these supplements could be beneficial for them.

Details

Use the full description to understand the study design, methods, and the limits of the findings.

This study followed participants from the AREDS2 trial over a decade to understand the effects of different supplements on eye health.

  • Participants were randomly assigned supplements including lutein/zeaxanthin or beta-carotene and followed for ten years.

  • Results showed that lutein/zeaxanthin was associated with a reduced risk of advanced AMD, while beta-carotene increased lung cancer risk, especially in former smokers.

  • The study highlighted the importance of choosing the right supplements for eye health, but noted limitations such as self-reported data and the study's observational nature.

Seniors should talk to their doctors about whether lutein and zeaxanthin could be a safe and effective option for maintaining eye health.

Research Quality Score

Scored October 15, 2026 using rubric mq-1.8_2026-07-06.

Assessment

The study scores well in design due to its basis in a prior RCT, but the follow-up is observational. Bias control is limited by the lack of blinding in the follow-up. Statistical integrity is affected by the lack of multiplicity adjustment. Transparency is moderate with adherence to STROBE but no pre-registration. Conflicts are noted due to NIH's financial ties. The study is relevant to older adults and published in a high-quality journal.

Category Breakdown

CategoryScoreRating
Study design6.7/10
Bias control3.3/10
Statistical methods5.0/10
Reporting completeness5.0/10
Conflicts & funding7.5/10
Replication5.0/10
Relevance to chosen population10.0/10
Journal Reliability5.0/10

Additional Notes

The study evaluates the long-term effects of lutein/zeaxanthin in AREDS2 supplements on AMD progression and lung cancer risk, finding lutein/zeaxanthin reduces AMD progression risk without increasing lung cancer risk.

Assessed on the study's full text across 8 quality dimensions; conflict-of-interest disclosures were reviewed.

Take the next step

Build a personalized plan using research-backed studies, conditions, and treatments.